

## Quality of Life Assessment in Cancer Studies

**Target Audience:** Researchers, clinicians, statisticians, and healthcare professionals from academia, pharmaceutical companies, NHS, and regulatory and health technology assessment agencies

#	Session	Topics/Aims
01	<b>Overview of the Course</b>	<ul style="list-style-type: none"><li>• Welcome and Introduction</li></ul>
02	<b>Patient and Public Involvement (PPI) in QoL</b>	<ul style="list-style-type: none"><li>• A patient view: why quality of life (QoL) matters to patients, clinicians, and researchers, and why it needs to be collected in clinical trials</li></ul>
03	<b>The Importance of QoL Assessment and Choosing QoL Questionnaires in Cancer</b>	<ul style="list-style-type: none"><li>• Definition of QoL and how it is measured</li><li>• Characteristics of QoL questionnaires (items, dimensions)</li><li>• How to choose a patient-reported outcome measure: generic vs disease-specific instrument</li></ul>
	<b>Break</b>	
04	<b>QoL in Cancer Clinical Trials: Design and Outcomes</b>	<ul style="list-style-type: none"><li>• What happens to QoL: improvement, stability or deterioration</li><li>• Role of QoL in superiority and non-inferiority/head-to-head trials</li><li>• Incorporating QoL into trial design (including sample size)</li><li>• Administration of QoL assessments (adults, paediatrics, carers, computer-adaptive instruments)</li></ul>
	<b>Lunch Break</b>	
05	<b>Analysis and Interpretation of QoL Results</b>	<ul style="list-style-type: none"><li>• How QoL is analysed: overview of common approaches</li><li>• Interpreting QoL results (e.g. effect sizes, thresholds, minimal clinically important differences)</li><li>• Presentation of QoL data (tables and graphs)</li></ul>
06	<b>Group Workshop</b>	<ul style="list-style-type: none"><li>• Incorporating QoL into Trial Protocols and Grant Applications</li><li>• Group discussion of case studies of QoL</li></ul>
	<b>Break</b>	
07	<b>Using QoL for Decision-Making</b>	<ul style="list-style-type: none"><li>• QoL in regulatory and market access/reimbursement evaluations</li><li>• Societal impacts: e.g. indirect costs, productivity losses</li><li>• The role of QoL in cost-effectiveness analyses</li></ul>
08	<b>Closing Remarks</b>	<ul style="list-style-type: none"><li>• Summary of key takeaways</li><li>• Q&amp;A and final discussion</li></ul>